Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

Ana Garcia Garcia de Paredes, Càndid Villanueva,Carolina Blanco, Joan Genescà,Nicolo Manicardi,Juan Carlos Garcia-Pagan,Jose Luis Calleja,Carlos Aracil,Rosa M Morillas,Maria Poca,Beatriz Peñas,Salvador Augustin,Juan G Abraldes, Eldimar Alvarado,Félix Royo,Maria Laura Garcia-Bermejo,Juan Manuel Falcon-Perez, Rafael Bañares,Jaime Bosch,Jordi Gracia-Sancho, Agustin Albillos

JHEP Reports（2021）

引用 5|浏览28

暂无评分

摘要

•miR-181b-5p appears to be a useful serum biomarker to anticipate ascites onset.•Low serum miR-181b-5p indicates low risk of ascites in compensated cirrhosis.•Low serum miR-429 reflects acute hemodynamic response to non-selective beta-blockers.

查看译文

关键词

Ascites,beta-blockers,cirrhosis,microRNA,portal hypertension

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要